Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

1,803 recalls · Class II, newest first

Risk Class IClass IIClass III
Status OngoingCompletedTerminated
Year 20262025202420232022 2013 All years
Cause Sterility / contaminationNitrosamine impurityChemical / undeclaredParticulate / foreign matterLabeling / mix-upcGMP deviationMicrobial contamination All causes
Class II · Moderate risk

VECURONIUM Bromide for Injection

CGMP Deviations: product was not manufactured under current good manufacturing practices which contributed to Failed Impurities/Degradation Specifications as a high out of specification impurity result was detected during routine quality testing of stability samples.

Terminated Impurity / degradation Sagent Pharmaceuticals Inc NDC 25021-657-10 D-605-2013
Class II · Moderate risk

Parsel Plus

Defective container: products are packaged in pouches which may not have been fully sealed

Terminated Packaging defect Novartis Consumer Health D-846-2013
Class II · Moderate risk

No Doz

Defective container: products are packaged in pouches which may not have been fully sealed

Terminated Packaging defect Novartis Consumer Health D-845-2013
Class II · Moderate risk

Excedrin Migraine

Defective container: products are packaged in pouches which may not have been fully sealed

Terminated Packaging defect Novartis Consumer Health D-844-2013
Class II · Moderate risk

Excedrin Extra Strength

Defective container: products are packaged in pouches which may not have been fully sealed

Terminated Packaging defect Novartis Consumer Health D-843-2013
Class II · Moderate risk

0.9% Sodium Chloride Injection

Lack of Assurance of Sterility: The product has the potential for solution to leak at or near the administrative port of the primary container.

Terminated Sterility / contamination Hospira Inc. NDC 0409-7983-02 D-608-2013
Class II · Moderate risk

VersaPharm Incorporated

Discoloration: Ethambutol HCl Tablets 400 mg is being recalled due to a Out of Specification result for description testing for a surface defect of ink.

Terminated Failed specification West-Ward Pharmaceutical Corp. NDC 61748-014-06 D-839-2013
Class II · Moderate risk

Cleocin Phosphate

Presence of Particulate Matter: Firm is recalling a small number of vials with very small reflective flakes consistent with delamination of the glass vial.

Terminated Particulate / foreign matter Pharmacia & Upjohn LLC D-609-2013
Class II · Moderate risk

Cefazolin

Lack of Assurance of Sterility: Sandoz Inc is recalling Cefazolin for Injection, USP 1 gm vials, lot DB2208, due to a customer complaint for broken/cracked vials which was confirmed through review of retained samples.

Terminated Sterility / contamination Sandoz Incorporated NDC 00781-3451-70 D-597-2013
Class II · Moderate risk

Yohimbine 10 mg/ml Injection

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes

Ongoing Sterility / contamination Lowlite Investments, Inc. D/B/A Olympia Pharmacy D-796-2013
Class II · Moderate risk

Xylazine 300 mg/ml Injection

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes

Ongoing Sterility / contamination Lowlite Investments, Inc. D/B/A Olympia Pharmacy D-795-2013
Class II · Moderate risk

Vitamin B-Buildup Injection

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes

Ongoing Sterility / contamination Lowlite Investments, Inc. D/B/A Olympia Pharmacy D-793-2013
Class II · Moderate risk

Vitamin B12

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes

Ongoing Sterility / contamination Lowlite Investments, Inc. D/B/A Olympia Pharmacy D-791-2013
Class II · Moderate risk

Vitamin 15

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes

Ongoing Sterility / contamination Lowlite Investments, Inc. D/B/A Olympia Pharmacy D-789-2013
Class II · Moderate risk

Trimix

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes

Ongoing Sterility / contamination Lowlite Investments, Inc. D/B/A Olympia Pharmacy D-787-2013
Class II · Moderate risk

Testosterone Cypionate

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes

Ongoing Sterility / contamination Lowlite Investments, Inc. D/B/A Olympia Pharmacy D-786-2013
Class II · Moderate risk

Taurine 100 mg/ml Injection

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes

Ongoing Sterility / contamination Lowlite Investments, Inc. D/B/A Olympia Pharmacy D-785-2013
Class II · Moderate risk

Tacrolimus

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes

Ongoing Sterility / contamination Lowlite Investments, Inc. D/B/A Olympia Pharmacy D-784-2013
Class II · Moderate risk

Stanozolol

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes

Ongoing Sterility / contamination Lowlite Investments, Inc. D/B/A Olympia Pharmacy D-783-2013
Class II · Moderate risk

Sodium Tetradecyl Sulfate

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes

Ongoing Sterility / contamination Lowlite Investments, Inc. D/B/A Olympia Pharmacy D-782-2013

Recalls by year